News & Updates
Showing Multidisciplinary articles
Showing
SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
Modified Atkins diet may be better than keto for childhood drug-resistant epilepsy
Dietary modifications offer short-term benefits in children with drug-resistant epilepsy, but modified Atkins diet appears more tolerable and more likely to reduce the frequency of seizures than ketogenic diet, as shown in a study.
Dupilumab yields rapid, lasting improvement in erythrodermic atopic dermatitis
Treatment with dupilumab helps improve the signs and symptoms of erythrodermic atopic dermatitis, with the improvements occurring as early as the first week and being sustained over time, according to a study. The drug has an acceptable safety profile.
Hormone therapies up ILD events in men with prostate cancer
Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.